Drug Interaction Study of Warfarin and MT-3995

Inclusion Criteria: * Able and willing to provide written informed consent to participate in this study * Healthy, free from clinically significant illness or disease * White Caucasian male or female, aged 18 to 55 years * Body weight ranging from 50 (females) and 60 (males) to110 kg (inclusive) * Must have coagulation test results (including international normalised ratio \[INR\] and activated partial thromboplastin time \[aPTT\]) within the laboratory reference range at Screening. Exclusion Criteria: * Presence or history of serious adverse reaction or allergy to any medicinal product * Known contraindication or adverse reaction to warfarin. * Presence of Cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase complex subunit 1 (VKORC1) genetic polymorphisms that are known to increase warfarin sensitivity at Screening. * Known contraindications to heparin administration. * Known contraindication to parenteral vitamin K administration.